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Abstract: The development and in vitro performance of a modular nanoscale system capable 
of speciﬁ  c structural modiﬁ  cation by enzymatic activity is described in this work. Due to its 
small physical size and adaptable characteristics, this system has the potential for utilization 
in targeted delivery systems and biosensing. Nanoparticle probes were synthesized containing 
two distinct ﬂ  uorescent species including a quantum dot base particle and ﬂ  uorescently labeled 
cleavable peptide substrate. Activity of these probes was monitored by gel electrophoresis with 
quantitative cleavage measurements made by ﬂ  uorometric analysis. The model proximity-
activated nanoparticles studied here exhibit signiﬁ  cant susceptibility to cleavage by matrix 
metalloprotease-7 (MMP-7) at physiologically relevant concentrations, with nearly complete 
cleavage of available substrate molecules after 24 hours. This response is speciﬁ  c to MMP-7 
enzyme activity, as cleavage is completely inhibited with the addition of EDTA. Utilization of 
enzyme-speciﬁ  c modiﬁ  cation is a sensitive approach with broad applications for targeted thera-
peutics and biosensing. The versatility of this nanoparticle system is highlighted in its modular 
design, as it has the capability to integrate characteristics for detection, biosensing, targeting, 
and payload delivery into a single, multifunctional nanoparticle structure.
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Introduction
Localized or speciﬁ  c delivery of therapeutics to diseased cells represents a historic 
paradigm shift in the treatment approach toward many disease states, including vari-
ous types of cancer. Traditional approaches utilize systemic administration of highly 
potent drugs in an attempt to eradicate neoplastic cells, often with signiﬁ  cant toxic 
side effects. Initial attempts at targeted delivery of these drugs have focused on the 
incorporation of small ligands to direct the therapy to a speciﬁ  c target site (Sachdeva 
1998; Hallahan et al 2001; Pastorino et al 2003; Mitra et al 2005). However, the cur-
rent generation of targeted therapies has not yet generally achieved highly speciﬁ  c 
localization to tumors and emerging neoplasia through a single recognition mechanism 
(Bogenrieder and Herlyn 2003; Kim and Toge 2004). Nonspeciﬁ  c binding and spe-
ciﬁ  c binding to nontarget cells compromise the therapeutic index of small molecule, 
ubiquitous cancer targeting ligands, and limits their applicability and efﬁ  ciency as 
primary chemotherapeutic agents.
An alternative targeting approach involves the use of molecules capable of activa-
tion following cleavage by tumor- or other tissue-speciﬁ  c enzymes. These compounds 
have been incorporated into many structures ranging from in vivo imaging constructs 
(Weissleder et al 1999; Tung et al 2000; McIntyre and Matrisian 2003; Harris et al 
2006) to chemically modiﬁ  ed drug structures in the form of prodrugs (Suzawa et al 
2000, 2002; Liu et al 2003). These studies demonstrate the feasibility of tumor-speciﬁ  c International Journal of Nanomedicine 2008:3(1) 96
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enzyme interaction as a means of modifying the physical 
structure of delivered drugs and imaging constructs, and 
potentially enables targeted delivery of drug carriers, includ-
ing nanoparticles (NPs).
Several studies utilizing this approach have focused 
on the development of tumor-speciﬁ  c molecular imaging 
constructs cleavable by matrix metalloproteases (MMPs), 
including speciﬁ  c cleavable peptide sequences (Bremer et al 
2001, 2002; Zucker and Cao 2001; McIntyre and Matrisian 
2003; McIntyre et al 2004). The basis of the MMP-7 spe-
ciﬁ  c peptide substrate (RPLALWRS) utilized in one such 
report (McIntyre et al 2004) is employed in this study to 
impart tumor-speciﬁ  c activity to our NP proximity activated 
system.
The role of MMP-7 in biological 
processes
MMPs (including MMP-7) are a family of extracellular, 
zinc-dependent proteases that have a role in tissue breakdown 
and remodeling during both normal (eg, angiogenesis, gut 
innate immunity) and pathological (eg, inﬂ  ammation, tumori-
genesis, metastasis) processes. MMP-7 is important in the 
progression of a number of tumors, notably those originating 
in the colon or breast (McIntyre et al 2004). Furthermore, 
MMP-7 has proven to have diagnostic and prognostic value, 
as expression is associated with poor outcome in esophageal 
(Yamamoto et al 1999), colon (Adachi et al 2001), and pan-
creatic (Yamamoto et al 2001) cancers.
For tumor systems in which MMP-7 activity is known 
to modulate the course of the disease, MMP-7 is secreted 
even in the earliest stages. Small, benign “precancerous” 
lesions, for example, exhibit MMP-7 secretion well before 
these lesions would be clinically detectable (Crawford et al 
2002; Hulboy et al 2004). Furthermore, analysis of MMP-7 
expression in human neoplasia revealed that enzyme mRNA 
appeared in the surrounding normal tissue in only a few 
isolated cases (Wilson and Matrisian 1996), suggesting 
highly speciﬁ  c enzyme expression in the immediate tumor 
vicinity.
Nanoparticle-based therapeutic 
systems
Literature citations of tumor-speciﬁ  c cleavable constructs 
focus mainly on molecular imaging of enzyme activity and 
drug activation in vivo. However, incorporation of these 
constructs into NPs or their application to target NP-based 
therapeutic systems is an exciting area of opportunity. One 
recent study (Zhang et al 2006) has incorporated cleavable 
MMP substrates into NPs via a biotin-streptavidin linkage, 
outlining one method utilizing speciﬁ  c enzymatic activity 
to modulate NP uptake and delivery to cells. The work 
described here offers a conjugation approach that eliminates 
the need for biotin-streptavidin, resulting in a multifunctional 
nanoscale construct with novel characteristics. Importantly, 
studies described here include quantitative examination of 
NP construct cleavage and activation, providing a robust 
basis for further in vitro and in vivo targeting, delivery, and 
sensing applications.
Particulate systems have inherent advantages for these 
applications, in part, due to their relatively large surface to 
volume ratio, allowing the conjugation of multiple active 
molecules directly to the particle surface. Stable covalent 
conjugation of a range of bioactive molecules such as 
enzymes (Phadtare et al 2004; Rossi et al 2004; Kuhn et al 
2006, 2007), mAbs (Tang et al 2005), peptides (Liu et al 
2001), and DNA (Wang et al 2003; Zhang et al 2004) to 
the surface of NPs has been reported. Direct conjugation of 
ligands to the NP surface may overcome signiﬁ  cant obstacles 
inherent in the ubiquitous biotin-streptavidin system, includ-
ing immunogenicity, increased molecular size (primarily due 
to the relatively large molecular mass of streptavidin), and 
limited in vivo application. With small molecule ligands, 
many functional copies can potentially be directly attached 
to the surface of the NP enabling multiplexed interaction 
with target cells. In addition to these attractive nanoparticle 
characteristics, quantum dots (QDs) offer the added beneﬁ  t 
of intense ﬂ  uorescence characteristics for highly sensitive 
detection and imaging. The combination of these attributes 
impart the capability to integrate speciﬁ  c delivery, detec-
tion, imaging, and treatment characteristics into a single, 
multifunctional NP delivery vehicle.
In this study, we describe the synthesis and in vitro per-
formance of a NP probe capable of speciﬁ  c activation by 
MMP-7. In addition, the importance of quantitative analysis 
of construct performance is described in the context of in 
vitro and in vivo application. To construct the proximity 
activated NP, a carboxylated QD was functionalized with 
a peptide construct (PEG3400-[Ahx]-RPLALWRS-[Ahx]-
PEG5000-K(5-FAM); PA construct). The PA construct con-
sists of an 8-mer peptide substrate (RPLALWRS) cleavable 
by MMP-7. The PA construct also contains polyethylene gly-
col (PEG) groups to reduce nonspeciﬁ  c binding. Therefore, 
the PA construct initially presents as a PEGylated nanopar-
ticle with low nonspeciﬁ  c binding as predicted from previous 
studies (Akerman et al 2002; Ballou et al 2004; Gao et al 
2004). Cleavage of the internal peptide liberates the distal International Journal of Nanomedicine 2008:3(1) 97
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PEG and part of the peptide, along with a ﬂ  uorophore, in 
this work, for assessment of cleavage (Figure 1). In the 
future, proteolytic modiﬁ  cation could be used to “unmask” 
the particle, enabling access to underlying small molecule 
ligands previously concealed near the nanoparticle surface. 
Effective PA targeting will likely be modulated by many 
molecular factors, including the relative characteristics of 
the distal and proximal PEGs on the PA construct and the 
PEG (or other molecular spacer) that displays the ligand 
from the nanoparticle surface.
Materials and methods
Cleavable peptides and NP probes
The PEGylated substrate for MMP-7 (PEG3400-[Ahx]-
RPLALWRS-[Ahx]-PEG5000-K(5-FAM; PA construct) 
was obtained from Anaspec. This structure consists 
of a cleavable 8-mer peptide substrate (RPLALWRS) 
ﬂ  anked by polyethylene glycol (PEG) groups of 3400 
and 5000 g/gmol and aminohexanoic acid (Ahx) groups 
to serve as spacer molecules, as well as a ﬂ  uorescent tag 
(5-FAM) for cleavage detection. The N-terminus of the 
construct was a primary amine to facilitate further con-
jugation reactions. To stabilize the substrate and prevent 
additional modiﬁ  cation, C-terminal amidation was per-
formed during synthesis.
The N-terminal amine group of the substrate was conju-
gated to the surface of carboxylate QDs (CdSe dots coated 
with ZnS, 585 nm emission; Quantum Dot Corp., Hayward, 
CA) using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC). 250 µl of QDs (7.5 µM) was diluted to 1 µM with 
10 mM borate buffer, pH 7.4. 80 µL from a 10 mg/mL 
stock solution of the cleavable PA substrate was added to 
the solution, yielding a PA:QD molar ratio of 10.0:1. 57 µl 
from a 10 mg/ml stock solution of EDC was added and the 
mixture was stirred for 2 h at room temperature to complete 
the conjugation. Unconjugated PA construct was removed by 
performing three buffer exchanges in a 50,000 Da nominal 
molecular weight limit (NMWL) cutoff spin ﬁ  lter device 
(Amicon Ultra). The concentration of the ﬁ  nal puriﬁ  ed prod-
uct was determined by measuring the absorbance at 575 nm 
using a QD extinction coefﬁ  cient of 400,000 M−1cm−1.
MMP-7 activity assay
Studies were conducted to determine the susceptibility of 
both the PA and QD-PA constructs to exogenous MMP-7. 
Active MMP-7 (Calbiochem) was added to 100 µl of a 
50 nM PA or QD-PA solution in borate buffer (pH 7.4) 
supplemented with 50 µM ZnSO4. The total concentration of 
MMP-7 was varied in these samples from 100 nM to 5 nM. 
Samples were then incubated at 37 °C for various timepoints 
ranging from 1 h to 48 h. Control studies involving QD-PA 
with no enzyme and with inactivated enzyme (by addition 
of 30 mM EDTA) were carried out simultaneously for direct 
comparison. In the case of QD-PA constructs, any cleavage 
products were removed by spin ﬁ  ltration in a 50,000 NMWL 
cutoff device.
Gel electrophoresis
PA constructs were analyzed on a 10%–20% gradient tris-
tricine polyacrylamide gel (Life Gels). Samples were loaded 
in a buffer containing 10% glycerol in tris-tricine running 
buffer (Life Gels). Gels were then run under a 150 mV voltage 
for ∼1 h. Control, unconjugated PA constructs were compared 
with cleaved PA constructs to straightforwardly visualize and 
conﬁ  rm enzymatic activity against the substrate.
A quantitative determination of PA construct cleavage 
was made by digital analysis of gel electrophoresis images. 
Gel images were obtained as JPEG ﬁ  les and visually analyzed 
Figure 1 Schematic of QD-PA synthesis and subsequent cleavage.International Journal of Nanomedicine 2008:3(1) 98
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in Doc-It LS software (UVP Inc.). Regions of interest 
were drawn around individual bands, and each band was 
electronically cut from the image and saved as a separate 
JPEG ﬁ  le. These ﬁ  les were loaded into a simple MATLab 
script designed to calculate quantitative image parameters. 
The composite ﬂ  uorescence intensity for each band was 
calculated by correcting for background intensity and then 
summing the measured intensity of each pixel contained in 
the image. The relative percentage contained in each band 
was obtained by comparing its composite ﬂ  uorescence to 
that of the total for the lane.
QD-PA constructs were assayed by loading samples 
directly on to a 0.8% bufferless agarose gel (E-Gel, Invit-
rogen Corp.). QDs subjected to the cleavage reaction were 
assayed against native carboxylate QDs, uncleaved QD-PA 
constructs, and QD-PA + EDTA. All gels were imaged for 
ﬂ  uorescence on a BioDoc-It imaging system (UVP Inc.).
Fluorescence spectroscopy
Following PA conjugation and puriﬁ  cation, the ﬂ  uorescence 
spectra of QD-PA constructs were measured by ﬂ  uorescence 
spectroscopy at 488 nm excitation (Perkin-Elmer LS 50B). 
Enzymatic cleavage of the QD-PA constructs was monitored 
by measuring changes to the ﬂ  uorescence spectra follow-
ing incubation with MMP-7. The spectra were scaled to 
normalize QD peak ﬂ  uorescence (∼585 nm) between all 
samples. The peak ﬂ  uorescence intensity values at ∼519 nm 
and ∼585 nm were then directly compared to the spectra of 
control, uncleaved QD-PA particles to calculate the extent of 
PA construct cleavage following MMP-7 treatment.
Size measurements
Nanoparticle size was determined using dynamic light 
scattering (DLS) measurements. DLS measurements were 
conducted on a Malvern Nano Series Zetasizer with a 633 nm 
laser. The duration of the scans was 60 s, and 3 scans were 
accumulated. The concentration of all QD samples was 
0.25 µM.
Statistics
Statistical signiﬁ  cance of experimental populations was 
assessed using an upaired t-test and determined by Sigma-
Stat (Jandel Scientiﬁ  c Software). Differences were termed 
signiﬁ  cant for p  0.05.
Results and discussion
In vitro cleavage of the PA construct
The PA construct is highly susceptible to cleavage by MMP-7. 
Prior to conjugation to the QD surface, PA constructs were 
assayed for susceptibility to enzymatic activity. Analysis 
of gel electrophoresis images of unconjugated PA (prior to 
conjugation to the NP surface) conﬁ  rms speciﬁ  c cleavage of 
these constructs by MMP-7 (Figure 2). Lanes 1 and 2 conﬁ  rm 
the presence of the intact, ﬂ  uorescently labeled PA structure. 
These bright, low mobility bands are nearly extinguished 
after 24 h exposure to MMP-7. This cleavage also results 
in the generation of a very bright, high mobility band cor-
responding to the low molecular weight, labeled cleavage 
product (Figure 2, lanes 3 and 4). PA construct cleavage was 
completely abolished by the addition of 30 mM EDTA (a zinc 
chelator; Figure 3, lanes 5 and 6), as the band corresponding to 
Figure 2 Gel electrophoresis conﬁ  rms cleavage of the soluble, unconjugated PA construct by MMP-7. Lanes 1 and 2 show the unconjugated PA construct prior to enzy-
matic exposure as a control. The bright, low mobility band (identiﬁ  ed by the white arrow) represents the intact high molecular weight PA structure. Lanes 3 and 4 represent 
the PA construct exposed to MMP-7 for 24 hours, while lanes 5 and 6 show the inhibition of MMP-7 activity by EDTA.International Journal of Nanomedicine 2008:3(1) 99
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the cleaved PA construct is absent in these wells. These results 
are consistent with the near complete proteolysis of the PA 
construct at the site of the MMP target peptide and inhibition 
of the zinc-dependent MMP-7 enzyme by EDTA.
A quantitative determination of PA construct cleavage 
was made by digital analysis of gel electrophoresis images. 
From this analysis, the percentage of PA construct contained 
in each sample was determined. Control, uncleaved soluble 
PA construct contains 35.6 ± 3.4% intact PA structure, as 
determined from 4 independent trials. The remaining 64.4% 
of the ﬂ  uorescence intensity in these bands represents high 
mobility structures consistent with 5-FAM labeled reactants 
and intermediates. 4.6 ± 0.7% of the intact PA structure 
remains after exposure to 100 nM MMP-7 for 24 hours. 
Therefore, 87.2 ± 0.7% of the initial intact PA construct 
was cleaved (p  0.001) and 12.8 ± 0.7% remained intact 
after enzymatic exposure, conﬁ  rming the high susceptibility 
of the PA construct to MMP-7 proteolysis. Samples treated 
with MMP-7 + 30 mM EDTA contain 35.5 ± 2.0% intact 
PA structure, a value equivalent to the amount measured in 
control samples in the absence of MMP-7 (p = 0.966).
QD-PA construct synthesis and activity
The surface of carboxylate QDs was successfully modiﬁ  ed 
with the PA construct. This was evident as the size of the 
nanoparticle increased after functionalization. The size of 
the unmodiﬁ  ed QD is 18.2 ± 0.3 nm, according to dynamic 
light scattering (DLS) measurements. After functionaliza-
tion, the size of the quantum dot functionalized with the PA 
construct (QD-PA) is 81.8 ± 10.5 nm. Additionally, agarose 
gel electrophoresis shown in Figure 3 reveals that conjugation 
of the PA construct to the QD surface results in a signiﬁ  cant 
decrease in electrophoretic mobility (lane 4) over unmodiﬁ  ed 
carboxylate QDs (lane 3), presumably corresponding to an 
increase in MW and surface charge characteristics of the QD 
following PA conjugation. MMP-7 treatment results in partial 
recovery of mobility (lane 5), consistent with a reduction of 
surface-associated molecular mass mediated by proteolytic 
cleavage. Mobility recovery is not complete, consistent with 
persistence of the proximal portion of the PA construct on 
the QD surface after proteolytic cleavage. MMP-7 mediated 
increase in mobility is reversed with the addition of 30 mM 
EDTA during cleavage (lane 6), suggesting inhibition of 
MMP-7 activity by EDTA. Changes in relative mobilities 
provide evidence of successful QD surface functionalization, 
subsequent proteolytic degradation, and inhibition of enzyme 
activity expected in this system.
QD-PA synthesis and activity was further conﬁ  rmed 
by measuring the ﬂ  uorescence spectra of the resulting con-
jugates. Following conjugation and puriﬁ  cation, the ﬂ  uo-
rescence spectra of the QD-PA constructs were measured 
(Figure 4). These spectra reveal ﬂ  uorescence maxima at 
approximately 520 and 585 nm, corresponding to the emis-
sion maxima of the 5-FAM labeled PA construct (519 nm) 
and of the QD base (585 nm), respectively.
Enzymatic cleavage was monitored by measuring changes 
to the ﬂ  uorescence spectra of the QD-PA constructs follow-
ing incubation with MMP-7 (Figure 4, QD-PA + 100 nM 
MMP-7). Relative to control, uncleaved QD-PA constructs, 
these spectra reveal a reduced ﬂ  uorescence peak at 519 nm, 
suggesting loss of 5-FAM ﬂ  uorescence from the QD-PA 
construct, consistent with proteolysis of the PA construct at 
the site of the MMP-7 target peptide and subsequent removal 
of cleavage products. This result is consistent with gel 
Figure 3 The surface of carboxylate QDs was successfully functionalized with the 
cleavable PA construct. Mobility of QDs modiﬁ  ed with the cleavable PA construct 
(lane 4, diffuse band) is reduced compared with that of unmodiﬁ  ed QDs (lane 3). 
24 h exposure of the QD-PA conjugates to MMP-7 (lane 5) leads to a partial recov-
ery of mobility, Increased mobility after exposure to MMP-7 can be completely 
inhibited by the addition of 30 mM EDTA (lane 6). This image is representative of 
three independent trials.International Journal of Nanomedicine 2008:3(1) 100
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electrophoresis images and computed results, demonstrating 
retention of PA proteolytic susceptibility following conjuga-
tion to the QD surface. Additional studies revealed no signiﬁ  -
cant photobleaching of either 5-FAM or QD over the course 
of the measurements. Furthermore, no signiﬁ  cant change in 
QD ﬂ  uorescence intensity (at 585 nm) was observed upon 
PA cleavage from the surface.
Fluorescence measurements were used to produce a 
quantitative analysis of PA construct cleavage. These mea-
surements (Figure 5) conﬁ  rm signiﬁ  cant cleavage of the PA 
construct from the QD surface. Cleavage increased steadily 
with incubation time, reaching a plateau after 24 h (90.9 ± 
15.4% cleavage), consistent with cleavage of unconjugated 
PA constructs under the same conditions (87.1 ± 0.7% 
cleavage). Measured cleavage values are highly dependent on 
incubation time, following an exponential rise to maximum 
curve describing traditional enzyme kinetics.
Cleavage of the PA construct from the QD surface was 
also inﬂ  uenced by initial MMP-7 concentration. Cleavage 
was measured from samples using MMP-7 concentra-
tions ranging from 100 nM to 5 nM (reﬂ  ecting the range 
of expected concentrations in vivo) as shown in Figure 6. 
Although the cleavage response measured for each MMP-7 
concentration follows the same general trend, the extent of 
cleavage is markedly altered, declining as MMP-7 concentra-
tion was reduced. Cleavage at early timepoints (t  6 h) is 
insensitive to MMP-7 concentrations above approximately 
10 nM.
Previous literature reports the Km of unmodiﬁ  ed PA 
substrate as 26 µM (Welch et al 1995). Thus, at substrate 
concentrations below this value, PA cleavage is expected to 
be independent of MMP-7 concentration. Bulk PA concen-
trations used in the current study range from 37.5–100 nM, 
well below the reported Km. However, at the given substrate 
concentration, and at low MMP-7 concentrations (eg, 5 nM 
and 10 nM), MMP-7 is the limiting reagent. At higher MMP-
7 concentrations (eg, 100 nM), MMP-7 concentration meets 
or exceeds substrate concentration. Thus, cleavage behavior 
transitions from a regime where MMP-7 is the limiting 
component to a regime where PA is the limiting component, 
resulting in measurements consistent with conventional 
enzyme kinetics.
Literature has shown that MMP-7 concentration can 
vary widely, with overexpression noted in various tumor 
phenotypes (McIntyre et al 2004). While few quantitative 
measures of MMP-7 concentration have been performed, 
Figure 4 QDs modiﬁ  ed with PA construct possess two ﬂ  uorescence emission peaks consistent with colocalized QD and PA construct ﬂ  uorescence. Exposure to MMP-7 
(dashed line) results in reduced 5-FAM ﬂ  uorescence intensity at approximately 520 nm when compared to control, uncleaved QD-PA samples (solid line). Results shown are 
representative of n  3 trials for all experimental groups.International Journal of Nanomedicine 2008:3(1) 101
Initial development of proximity activated nanoparticles
previous studies have utilized concentrations of up to 100 nM 
in vitro (Kioi et al 2003; Wang et al 2005), while others have 
measured comparable concentrations of additional MMPs 
in vivo (Furuya et al 2000). This evidence suggests likely 
local MMP-7 concentrations in tumor of at least 50 nM, 
corresponding with the levels utilized in the current study. 
Furthermore, our studies reveal that proteolytic susceptibility 
of QD-PA probes saturates at MMP-7 concentrations above 
10 nM. Thus, at enzyme concentrations at or above this 
threshold, QD-PA probes are expected to exhibit maximal 
activity.
As particle activation time and tissue residence time 
(ie, particle velocity) are competing factors, this ratio is an 
important consideration with potential for signiﬁ  cant impact 
on in vivo utility of QD-PA constructs. If activation time is 
long compared to residence time (eg, for vascular targets), 
then the NP will presumably be transported away during 
activation and before speciﬁ  c interaction can occur. In this 
case, PA delivery has characteristics similar to those for 
current targeted approaches. However, the small size and 
surface passivation (PEGylation) of the QD-PA construct 
combine to create a construct likely capable of extravasation 
and tumor accumulation, enabling access to targets within 
the tissue. In this compartment, particle transport is typically 
very slow, allowing ample time for particle activation. At 
the predicted tissue MMP-7 concentrations, QD-PA probes 
require 6 h for activation (deﬁ  ned as 50% cleavage), with 
signiﬁ  cant activity reached within 3 h. This activation time 
relates well to NP tissue residence times (Kaul and Amiji 
2004; Montet et al 2006), yielding probe performance char-
acteristics consistent with in vivo triggered targeting.
Conclusions
The QD-PA constructs described here could potentially 
provide a powerful, versatile platform for targeted delivery 
and biosensing for both in vitro and in vivo applications. 
Although the importance of therapeutic targeting has been 
acknowledged for more than two decades, few viable options 
for targeted therapy have been successfully implemented. 
Many treatment regimens continue to rely on systemic admin-
istration that compromises drug concentrations delivered to 
target tissue based on toxicity resulting from speciﬁ  c and 
nonspeciﬁ  c delivery to nontarget cells (Frei 1997).
The modular structure of the QD-PA constructs pro-
vides multiple parameters for performance optimization, 
with various factors presumably modulating the overall 
activity of the construct. Successful optimization requires 
consideration of the nanoscale, biological chemistry, and 
Figure 5 Fluorescence spectra of control, uncleaved QD-PA structures were compared to those of samples incubated with variable concentrations of MMP-7. Statistical 
measurements: * = p  0.05, **p  0.001. n  3 for all concentrations and timepoints.International Journal of Nanomedicine 2008:3(1) 102
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physiological transport of the overall construct. PEG length 
is one variable with potential to signiﬁ  cantly affect multiple 
characteristics including enzyme susceptibility (by limiting 
enzyme access to the substrate), nonspeciﬁ  c binding limita-
tion, effective ligand concealment (in future structures), and 
particle mobility. Additional structural parameters including 
enzyme substrate conﬁ  guration, ligand selection, and QD 
ligand surface density (number of molecules conjugated to 
the QD surface) can also directly affect probe performance. 
Tailoring of these multiple characteristics should enable 
optimization of probe performance for the requirements of 
both in vitro and in vivo systems.
PA targeting requires the colocalization of the cleavable 
mask and the targeting ligand, necessitating a particulate 
approach. In the exemplar described here, the NP is a 
QD, used to provide a ﬂ  uorescent beacon for performance 
assessment. Subsequent work will employ this construct, 
amended to include a targeting ligand, to assess proteolyti-
cally activated targeting in vitro and in vivo by quantitative 
ﬂ  uorescence measurements and ﬂ  uorescence imaging. While 
the appropriateness of QDs for clinical applications remains 
theoretically limited due to their heavy metal content, the 
PA targeting approach described here can be applied to 
other nanostructures approved for use in humans. These 
nanomaterials include iron oxide nanoparticles for magnetic 
resonance image contrast enhancement and drug delivery 
structures such as polymers, liposomes, polymersomes, and 
gene delivery vehicles.
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